MedKoo Cat#: 577748 | Name: Garsorasib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Garsorasib, also known as D-1553, is a potent and selective oral KRASG12C inhibitor. D-1553 showed selective and potent activity against mutated GDP-bound KRASG12C protein. D-1553 selectively inhibited ERK phosphorylation in NCI-H358 cells harboring KRASG12C mutation. Compared to the KRAS WT and KRASG12D cell lines, D-1553 selectively inhibited cell viability in multiple KRASG12C cell lines, and the potency was slightly superior to sotorasib and adagrasib. In a panel of xenograft tumor models, D-1553, given orally, showed partial or complete tumor regression. The combination of D-1553 with chemotherapy, MEK inhibitor, or SHP2 inhibitor showed stronger potency on tumor growth inhibition or regression compared to D-1553 alone.

Chemical Structure

Garsorasib
Garsorasib
CAS#2559761-14-5

Theoretical Analysis

MedKoo Cat#: 577748

Name: Garsorasib

CAS#: 2559761-14-5

Chemical Formula: C32H32F2N8O2

Exact Mass: 598.2616

Molecular Weight: 598.66

Elemental Analysis: C, 64.20; H, 5.39; F, 6.35; N, 18.72; O, 5.34

Price and Availability

Size Price Availability Quantity
5mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Garsorasib; D-1553; D 1553; D1553;
IUPAC/Chemical Name
7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one
InChi Key
DKFRWZJCNPETGI-SJORKVTESA-N
InChi Code
InChI=1S/C32H32F2N8O2/c1-4-24(43)40-13-17(3)41(14-16(40)2)30-20-12-22(34)28(25-21(33)6-5-7-23(25)35)38-31(20)42(32(44)39-30)29-26(18-8-9-18)36-15-37-27(29)19-10-11-19/h4-7,12,15-19H,1,8-11,13-14,35H2,2-3H3/t16-,17+/m1/s1
SMILES Code
O=C1N(C2=C(C3CC3)N=CN=C2C4CC4)C5=NC(C6=C(F)C=CC=C6N)=C(F)C=C5C(N7[C@@H](C)CN(C(C=C)=O)[C@H](C)C7)=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 598.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shi Z, Weng J, Niu H, Yang H, Liu R, Weng Y, Zhu Q, Zhang Y, Tao L, Wang Z, Huh SJ, Jiang Y, Mei H, Dai X, Zhang L, Wang Y. D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. Cancer Sci. 2023 Jul;114(7):2951-2960. doi: 10.1111/cas.15829. Epub 2023 May 9. PMID: 37158138; PMCID: PMC10323112. 2: Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, Zhou J, Jian H, Dong X, Zhuang W, Cang S, Yang N, Fang J, Shi J, Lu J, Ma R, Wu P, Zhang Y, Song M, Xu CW, Shi Z, Zhang L, Wang Y, Wang X, Zhang Y, Lu S. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results. J Thorac Oncol. 2023 Jul;18(7):940-951. doi: 10.1016/j.jtho.2023.03.015. Epub 2023 Mar 21. PMID: 36948246.